### Key Findings from the RISE Study on Type 2 Diabetes Prevention A major study called the RISE study has shown that common medications used to treat type 2 diabetes do not prevent prediabetes from progressing into full-blown diabetes. The study, published in June 2019, found that after 12 months of treatment with diabetes medications and three months off, the benefits disappeared in people with prediabetes. #### Study Details The study involved adults with prediabetes or early type 2 diabetes who were assigned to one of four treatment regimens: placebo pills, metformin alone, a long-acting insulin therapy known as Lantus (insulin glargine) followed by metformin, or the drug Victoza (liraglutide) plus metformin. Researchers followed participants for 12 months of active treatment and then reassessed them three months after stopping the therapy. #### Results The study found that while on medication, participants experienced benefits such as improved glucose tolerance. However, three months after stopping the medications, none of the subjects showed lasting benefits. This suggests that these medications do not provide a long-term solution for preventing the progression of prediabetes to type 2 diabetes. #### Implications The findings indicate that while medications like metformin, insulin glargine, and Victoza can provide short-term benefits, they do not offer a sustainable solution for preventing type 2 diabetes in people with prediabetes. This highlights the need for alternative strategies, such as lifestyle changes, to effectively manage and prevent the progression of prediabetes. #### Conclusion The RISE study underscores the importance of ongoing research to find effective, long-term strategies for preventing type 2 diabetes. While medications can offer temporary benefits, lifestyle changes such as diet and exercise remain crucial for long-term diabetes prevention.